Evidence map›Paper›PMID 35178218›Full record

ArticleCaspian journal of internal medicine2022

Ocular manifestation in a patient with IgG4 related disease.

Samaneh Azizimanesh, Fatema Rizvi, Hamed Zainaldain, Samira Alesaeidi

Open access · greenAbstract readCase Reports
In one paragraph

Article in Caspian journal of internal medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Samaneh AzizimaneshResearch Center for Rheumatologic Diseases, Amir-Alam Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Fatema RizviResearch Center for Rheumatologic Diseases, Amir-Alam Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Hamed ZainaldainResearch Center for Rheumatologic Diseases, Amir-Alam Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Samira AlesaeidiResearch Center for Rheumatologic Diseases, Amir-Alam Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Children's Medical Center · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIgG4-related disease is a newly recognized fibroinflammatory disease presenting with multiple features including mass forming lesion; a dense lymphoplasmacytic infiltrate; a characteristic histopathological appearance and often elevated serum of IgG4. This disease can potentially affect any organ and interestingly, the affected organs share common histopathological features including a dense lymphoplasmacytic infiltrate rich in IgG4-positive plasma cells, storiform fibrosis, and mild to moderate eosinophilia. CASE PRESENTATION: A 45-year-old man presented complaining of proptosis and gradual decrease in visual acuity of right eye. He had undergone many work-ups but without any definitive diagnosis. Through a combination of clinical and para-clinical investigations, the diagnosis of IgG4-RD was established. 693 mg/dL). Aggressive treatment (pulse of cyclophosphamide and pulse of corticosteroid) was started hoping to save the patient's vision. Two weeks following the treatment, there was improvement with his visual acuity and proptosis.

conclusionIn any patient with chronic tumor like lesions and pseudotumors without the evidence of malignancy, we should think of IgG4-related disease. In this circumstance, biopsy may lead us to the definitive diagnosis. Early diagnosis and treatment of IgG4-RD may inhibit further irreversible organ damages.

Indexed as

IgG4-related diseaseIgG4-related orbitopathyProptosis.Visual acuity

Identifiers

PMID35178218
PMCPMC8797814
OpenAlexW4213087127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.